Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer
Status:
Unknown status
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
This is an open label, monocentric, uncontrolled phase II trial with Dacomitinib, a pan-HER
inhibitor, in unresectable or metastatic skin SCC.
HER2 expression is common in skin SCC, being reported with high rates, even if in small
studies.
Coexpression of EGFR, HER2 and HER3 is present in skin SCCs but not in normal skin and it
could be associated with the malignant phenotype. In this frame Dacomitinib could play a role
in the increase of the response rate.
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano